CSOP Hang Seng Biotech ETF (03174.HK) Rises 1.80% Intraday as Hansoh Signs Roche ADC Deal with US$400 Million Upfront

NewTimeSpace News: As of 14:12 on October 20, the CSOP Hang Seng Biotech ETF (03174.HK) rose 1.80% to a latest price of HK$3.612. The ETF has traded 1.1068 million units so far today for a turnover of HK$3.9754 million at an average price of HK$3.592, with a turnover rate of 0.431%. It is up 1.80% so far this week. Its current net asset value per unit is HK$3.5707, and its assets under management stand at HK$917 million.

(Note on scope: the net asset value per unit and assets under management are as of October 16, 2026; the week-to-date change is measured against the closing price of HK$3.548 on October 16.)

On the news front, Hansoh Pharmaceutical announced after market close on October 19 that its wholly owned subsidiaries Shanghai Hansoh Biopharmaceutical, Changzhou Hengbang Pharmaceutical and Hansoh Bio, LLC had entered into a strategic collaboration and licence agreement with F. Hoffmann-La Roche — the two sides' second cooperation in the antibody-drug conjugate (ADC) field. The collaboration covers two preclinical Hansoh ADC assets and multiple ADC programmes on Roche-proposed targets powered by Hansoh's proprietary ADC platform; Hansoh will lead early development through global Phase Ia trials, and Roche will take over further global development excluding the Chinese Mainland, Hong Kong, Macao and Taiwan. Hansoh will receive an upfront payment of US$400 million plus a US$110 million first-anniversary payment, and is eligible for milestone payments potentially exceeding US$15 billion as well as tiered royalties. Hansoh shares rose more than 7% intraday on October 20; the company is one of the top-10 constituents of the Hang Seng Biotech Index.

The CSOP Hang Seng Biotech ETF (03174.HK) closely tracks the Hang Seng Biotech Index. The index reflects the overall performance of the 30 largest biotechnology companies listed in Hong Kong that are also eligible for Southbound trading, including pre-revenue companies listed under Chapter 18A of the Listing Rules; its constituents span the Hang Seng Industry Classification System sub-sectors of biotechnology, pharmaceuticals, pharmaceutical distribution, pharmaceutical and biotech contract services, and medical devices and supplies, and are weighted by freefloat market capitalisation with a 10% cap on any single constituent.

CITIC Securities noted that China's innovative drug industry has steadily improved fundamentals in the second half of 2026, driven by better R&D quality, global value validation and improved profitability, and that Chinese innovative drugs are gradually entering a stage of "global registration plus commercialisation delivery"; with WCLC, ESMO, ACR and ASH being held in succession, multiple registration studies are entering readout windows, global Phase III registration studies are advancing and overseas commercialisation is gradually materialising, which together are expected to drive the innovative drug sector.